Chemokines are small peptide mediators consisting of a group of small chemotactic cytokine proteins (<15 kDa) secreted by various cell types after induction or which may be constitutively expressed. 1 Chemokines influence migration, proliferation, angiogenesis, survival, and gene expression of a variety of cell types in their respective microenvironment.
determining the G protein-coupling and initializing the internalization of receptors (and the bound ligand) which is an important feature in the regulation of chemokine functions. 7, 8 In the case of CXCL12, the signaling mechanism is quite complicated as it signals via CXCR4 and/or CXCR7. This signaling system has been fondly referred to as the infernal trio.
2
| C XCL12
CXCL12 plays an essential role in physiologic conditions. 11 CXCL12
regulates development in multiple systems. 12 These include the hematopoietic, cardiovascular, and nervous systems and regulate diverse cell functions, including differentiation, distribution, activation, immune synapse formation, effector function, proliferation, and survival in the immune system. 12 Specifically, CXCL12 is known to drive lymphocyte and macrophage chemotaxis 13, 14 in pathophysiological settings of several systems. 13, 14 By contrast to its critical physiological role, CXCL12 has been implicated in several pathological states and is a known driver of chemotaxis via chemokine receptor CXCR4. This process is known to promote tumour growth and metastasis in at least 20 malignancies. 15, 16 Some examples of the pathophysiological involvement of CXCL12 are depicted and referenced in Table 2 and consist of cancer promotion, reproductive illness to periodontal disease. 15, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] A gradient of CXCL12 is established by secretion from inflammatory environments. Over the past decade, the involvement of chemokines and their respective receptors has been successively elucidated. It was initially thought that CXCR4 was the only receptor for CXCL12. In 2005, it was revealed that CXCL12 can bind a second chemokine receptor previously known as RDC-1 orACKR3. The receptor is now defined as CXCR7 with a 10-fold higher binding affinity for CXCL12 Figure 1 demonstrates the different binding processes and intermediates following CXCL12 binding.
| C XCL12 IS COMPRIS ED OF S E VER AL ISOFORMS
In addition to the complex mechanisms of the CXCL12/CXCR4/ CXCR7 signaling process, CXCL12 has been found to be expressed as different isoforms. The six splice variants of CXCL12 are identical in the first 88 amino acid residues from the amino terminus. 31 Although six different isoforms of human CXCL12 (α, β, γ, δ, ϵ, and ϕ) have been described, most studies of CXCL12 focus only on the α isoform or do not distinguish among isoforms. 15 
| C XCL12 S I G NALING VIA C XCR4, C XCR7, AND/OR C XCR-C XCR7 HE TEROD IMER S
When coexpressed, CXCR4 and CXCR7 may form homo-and heterodimers. Of note, heterodimerization seems to play an important role in the modulation of the down-stream signaling cascades. 2, 34, 35 At first, CXCR7 was regarded as a decoy receptor scavenging CXCL12 to prevent CXCR4 signaling and its respective effects. However, it has been since noted that the function of CXCR7 is controversial until further investigation can be conducted. 36 It was revealed that CXCL12-mediated activation of CXCR7 alone may evoke intracellular signaling events resulting in the recruitment of β-arrestin 30 which blocks activation. 
| C XCL12 S I G NALING IN ENDOME TRIOS IS
Endometriosis is a common gynecologic disorder characterized by the presence of hormonally responsive ectopic implants of endometrial epithelium and stroma dispersed in extrauterine locations. 37 Although the etiology is not fully characterized, endometriosis is a multifactorial disorder, resulting from retrograde menstruation, 38 Endometriosis has an estimated prevalence of 5%-10% among women of reproductive age, rising to 30%-50% in patients with infertility and/or pain. [43] [44] [45] [46] [47] Despite this estimated prevalence of disease, the etiology of endometriosis remains poorly understood. 38 Initial studies showed that human endometrial stromal cells produce the chemokine CXCL12 and that bone marrow cells express the CXCL12 receptor, CXCR4. 48 It was hypothesized that endometriosis lesions behave like chronically injured endometrium, producing high levels of CXCL12 and attracting bone marrow- However, the interaction between CXCL12 and CXCR7 on BMDSC attraction and disease progression remains to be determined.
| C XCL12 S I G NALING IN A S HERMAN ' S SYNDROME
In this section, we will address the endometrial disorder known as 
| C XCL12 S I G NALING IN LEI OMYOMA S
Leiomyomas (known as fibroids) are a common disease affecting up to 80% of women between 30 and 50 years of age. 55, 56 These tumours cause a variety of symptoms, including abnormal uterine bleeding, pelvic pain, bladder or bowel dysfunction, and recurrent pregnancy loss and are responsible for more than 200 000 hysterectomies in the United States. [43] [44] [45] [46] [47] 55 The estimated cost for treatment in the US population exceed $22 billion. 43 In addition to pain and infertility, fibroids have a significant social and psychological impact on the lives of women, 63% of whom report serious negative impact on their quality of life. Additionally, we demonstrate high expression of CXCR7 (Figure 2 ).
The overexpression of the axis is linked to tumour development, both through a direct modulation of neoplastic cell proliferation, survival, and migration, and, indirectly, acting on the tumour microenvironment. 58 Leiomyomas are benign tumours and exist in an inflammatory environment. We posit that this finding in leiomyomas makes these molecules potential targets which may lead to inhibition of disease progression in a nonhormonal fashion. It is known that in several diseases such as inflammatory bowel disease, 59 diabetes mellitus, 60 and various cancers, 61 the CXCL12-CXCR4/CXCR7 protein signaling axis is proinflammatory and furthers disease 62 Table 2 .
To date, these pathways have not been elucidated in benign tumours such as leiomyomas. We demonstrate by immunohistochemistry that CXCL12 and both its receptors (CXCR4 and CXCR7) are highly expressed within the fibroids of humans and nonhuman primates as opposed to low to no staining in control myometrium. We posit that this creates a feedforward loop within the tumours allowing aberrant cells to further proliferate. We propose that blocking this pathway will lead to new nonhormonal, or nonsurgical therapies and result in leiomyoma regression.
| C XCL12 S I G NALING IN OVARIAN C AN CER
Ovarian cancer is the fifth most common cause of cancer death among US women, and epithelial ovarian carcinoma is the leading cause of death from gynecologic cancers. 63 Recently, it has been demonstrated that signals mediated by the chemokine CXCL12 and its receptor CXCR4 are involved in the progression of ovarian cancer through enhancement of tumour angiogenesis and immunosuppressive networks that regulate dissemination of peritoneal metastasis and the development of cancer-inducing cells. 64 Signals mediated by the CXCL12/CXCR4 axis are centrally involved in ovarian cancer progression because CXCL12 can stimulate ovarian cancer cell migration and invasion through extracellular matrix, as well as DNA synthesis and establishment of a cytokine network in conditions that support tumour growth. 64 The authors surmised that modulation of the CXCL12/CXCR4 axis in ovarian cancer could impact multiple aspects of tumour pathogenesis, including immune dysregulation.
Several CXCR4 antagonists demonstrated antitumour efficacy in preclinical models. 64 Another recent study sought to identify the key factors and related pathways that can promote the establishment of ovarian cancer. 65 The authors note that ovulation is characterized by the production of cytokines and chemokines which results in follicle rupture and remodeling, immune cell infiltration, angiogenesis, and oocyte maturation. 65 They posit that these factors may also act as a chemo-attractants of malignant cells toward the ovaries. 65 The authors describe that superovulated murine models of ovarian cancer produced significantly higher doses of CXCL12. They further showed that blocking the CXCR4 receptor with AMD3100 repressed the migration of tumorigenic cells. axis may play an additional role in ovarian cancer. 67 Further analysis confirmed that CXCL12 enhanced cell adhesion and subsequent invasion, which were significantly attenuated when pretreated with CXCR7 small interference RNA (siRNA), indicating the critical function of CXCL12/CXCR7 in cell invasion. The authors further showed increased signaling via the p38 MAPK pathway. 67 These findings support the notion that the CXCL12/CXCR7 axis may represent another potential target in the treatment of ovarian cancer.
While the combined effects of the CXCL12/CXCR4/CXCR7 axis
have not yet been determined, the findings described above are encouraging toward the development of novel ovarian cancer treatments.
| C XCL12 S I G NALING IN ENDOME TRIAL C AN CER
Endometrial cancer is a clinically heterogeneous disease, and it is becoming increasingly clear that this heterogeneity may be a function of the diversity of the underlying molecular alterations. 68 In this study, the authors additionally demonstrated that CXCL-12 and CXCR7 were highly expressed in two endometrial cancer cell lines. These findings as well as others showed that EC cells were more effectively inhibited in the progression of disease by CXCR7-specific small molecule antagonists and less effectively inhibited by a CXCR4 antagonist. 69, 72 The authors suggest that based on these results, the biological functions in endometrial cancers may be controlled by CXCL12/CXCR7 rather than CXCL12/CXCR4 signaling.
However, as the CXCL12/CXCR4/CXCR7 is a complicated signaling pathway the authors warn that further clarification is required.
| CON CLUS IONS
In the current review, we demonstrate that the CXL12/CXCR4/ CXCR7 axis plays a key role in female reproductive tract disease. It is clear from the literature that the study of this axis is in its infancy and more research will be required to dissect out the role of the axis on the development or impediment of disease. Moreover, a search of the literature reveals that experiments regarding the CXCL12 variants in female reproductive tract disease have not been conducted.
The known CXCL12 isoforms result from alternative splicing events of the same gene. 32 Based on other studies unrelated to the female reproductive tract, it has been shown that CXCL12 variants are differentially involved in disease progression. These studies indicated that different polymorphisms were associated with an increased risk of HIV infection, lung cancer, breast cancer, acute leukemia, prostate cancer, non-Hodgkin's lymphoma, and oral squamous cell. 32, [73] [74] [75] [76] Therefore, it is proposed that these splice variants should be considered in further studies analyzing the role of the CXCL12/ CXCR4/CXCR7 axis.
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